{"entity":{"id":"dda-nepal","kind":"institution","name":"Department of Drug Administration, Nepal (DDA)","aka":["DDA Nepal","Department of Drug Administration","Aushadhi Byabastha Bibhag"],"tldr":"Nepal's medicines regulator, set up in 1979 to enforce the Drugs Act 1978. It registers medicines for import and local manufacture, inspects factories against GMP, and in 2026 issued notices on the supply of cancer medicines, platinum drugs among them.","summary":"The Department of Drug Administration was established by the Government of Nepal in 1979 (1 Kartik 2036 in the Nepali calendar), first under the Ministry of Forest and Soil Conservation and from 2041 under the Ministry of Health and Population, to implement the Drugs Act 1978. Its own page lists the Drug Registration Regulation 2038, the Drug Standard Regulation 2043, the medicine registration guidance of 2073, the National GMP Code 2072 and the National Drug Policy 1995 among its instruments, regional offices in Biratnagar, Birgunj and Nepalgunj, and a National Medicine Laboratory. It is based at Bijulibazar, New Baneshwor, Kathmandu; the coordinates are an approximate city point.\n\nThe imPACT reviewers wrote that oncology medicines are not produced in Nepal and come mainly from India or other countries, and that supply has always been a challenge. In 2026 the department's notice board carried notices titled on the availability of medicines used in cancer, on submitting details of essential medicines including platinum-group cancer drugs, on the availability of platinum-group medicines, and on introducing risk-based registration of medicines; their texts were published as images and were not read for this record.","asOf":"2026-11-11","links":[{"label":"DDA: about us (read through the Internet Archive, June 2025)","url":"https://web.archive.org/web/20250619222337/https://www.dda.gov.np/content/about-us"},{"label":"DDA: home page and notice board (read through the Internet Archive, October 2026)","url":"https://web.archive.org/web/20261012211112/https://dda.gov.np/"},{"label":"IAEA, WHO and IARC: imPACT Review summary report, Nepal (PDF)","url":"https://www.iaea.org/sites/default/files/documents/review-missions/nepal-impact-review-report-2022.pdf"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nepal-ministry-of-health-and-population"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Kathmandu","country":"NP","lat":27.69,"lng":85.33,"institutionType":"government","website":"https://www.dda.gov.np","programs":["Registration of medicines (Drug Registration Regulation 2038)","GMP inspection (National GMP Code 2072)","Pharmacovigilance and drug recalls","National Medicine Laboratory"]},"route":"/institutions/dda-nepal/","neighbours":{"institution":[{"id":"nepal-ministry-of-health-and-population","kind":"institution","name":"Ministry of Health and Population, Nepal","route":"/institutions/nepal-ministry-of-health-and-population/"}]}}